Type 2 Diabetes Mellitus is a Risk Factor for Skeletal Muscle Loss in the Course of Dietary Treatment for Patients with Metabolic Dysfunction-associated Steatotic Liver Disease-Reference-Cited by-同舟云学术

Type 2 Diabetes Mellitus is a Risk Factor for Skeletal Muscle Loss in the Course of Dietary Treatment for Patients with Metabolic Dysfunction-associated Steatotic Liver Disease

Published:2024 Issue: Volume: Page:
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Sano Akitoshi¹,Sasaki Manami²,Inoue Jun¹,Kakazu Eiji¹³,Ninomiya Masashi¹,Tsuruoka Mio¹,Sato Kosuke¹,Onuki Masazumi¹,Sawahashi Satoko¹,Ouchi Keishi¹,Doi Kotaro¹,Katori Yukio²⁴,Masamune Atsushi¹

Affiliation:

1. Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan

2. Department of Nutritional Management, Tohoku University Hospital, Japan

3. Department of Liver Disease, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Japan

4. Division of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, Japan

Publisher

Japanese Society of Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_3787-24/_pdf

Reference26 articles.

1. 1. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15: 11-20, 2018.

2. 2. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64: 73-84, 2016.

3. 3. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023 [Internet]. Available from: https://doi.org/10.1016/j.jhep.2023.06.003.

4. 4. Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. J Gastroenterol 56: 951-963, 2021.

5. 5. Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol 65: 1232-1244, 2016.